Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 18/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914497 | 0.86 | LMNA (0.41) | LMNAMAPK1KMT2AF10HPGD | |
| SCHEMBL4908280 | 0.75 | F10 (0.46) | LMNAMAPK1KMT2AF10F2 | |
| SCHEMBL4910098 | 0.72 | HPGD (0.45) | LMNAMAPK1F10HPGDTSHR | |
| SCHEMBL4909345 | 0.70 | HPGD (0.47) | LMNAMAPK1KMT2AF10HPGD | |
| SCHEMBL4910093 | 0.69 | HPGD (0.43) | LMNAMAPK1KMT2AF10HPGD | |
| SCHEMBL22051554 | 0.62 | MAPK1 (0.45) | LMNAMAPK1F10HPGDTSHR | |
| SCHEMBL3093673 | 0.62 | MIF (0.54) | LMNAMAPK1KMT2AF10F2 | |
| SCHEMBL17682014 | 0.62 | MAPK1 (0.59) | LMNAMAPK1KMT2AF10HPGD | |
| SCHEMBL16201598 | 0.61 | LMNA (0.55) | LMNAMAPK1KMT2AF10HPGD | |
| SCHEMBL8044210 | 0.61 | MIF (0.51) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | CYP11B2, CYP3A43, CYP11B1 | LMNA 1042/4885MAPK1 4379/4885KMT2A 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.